regorafenib
bayer
mart nez-lago et al. efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: the core study #wcgic2022 
Oncóloga medica y doctora en medicina. Tumores digestivos y neuroendocrinos en @chuaconco Medical Oncologist. MD PhD. GI and endocrine tumors.